Healthcare Industry News: Ampion
News Release - October 31, 2006
Ablatherm-HIFU Launches a New RPP Site in Spain; RPP Service Available in Madrid at ICUA ClinicLYON, France, Oct. 31 (HSMN NewsFeed) -- EDAP TMS S.A. (Nasdaq: EDAP ) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announces the launch of Ablatherm-HIFU services, in partnership with its Spanish distributor Davanzia, at Instituto de Cirugia Urologica Avanzada (ICUA), Madrid, Spain. The hospital will use the Ablatherm-HIFU device under EDAP's Revenue-Per-Procedure (RPP) model.
ICUA is a private medical clinic offering the most modern techniques, diagnostic capabilities and treatment technologies for urological pathologies. It is also active in research and academic trials. The Institute has a history of innovation including pioneering the Spanish use of laser therapy combined with HIFU to give the patient a faster recovery and fewer side effects during to the post-treatment period. ICUA previously pioneered cryosurgery and green light laser for prostate pathologies in Spain. Information regarding the clinic can be found online at http://www.icua.es .
The Ablatherm-HIFU treatment at ICUA has been successfully performed today by Dr. Fernando Gomez Sancha, a urological surgeon and Director of ICUA and head of the department of urology of USP Hospital San Jose in Madrid, Spain. Dr. Gomez Sancha specialized as a urological surgeon at the Hospital de La Princesa in Madrid, then subspecialized in reconstructive urology at the Institute of Urology in London. He founded ICUA and pioneered the application of photoselective vaporization of the prostate (PVP) for benign prostatic hyperplasia (BPH) in Spain. Dr. Gomez Sancha currently combines clinical work with academic and teaching activities training other doctors in these techniques throughout Spain and abroad. Details of his practice can be found online at http://drgomezsancha2.blogspot.com/ . Dr. Gomez Sancha trained with Drs. Murat and Gelet of Lyon, France in both first indication and radiation failure HIFU applications.
"I am very pleased and excited to play a role in bringing Ablatherm-HIFU to Spain," said Dr. Gomez Sancha. "This is a highly advanced and attractive new therapy addressing the needs of patients today as they seek less invasive but still very effective treatment choices. Ablatherm is unique in its ability to offer a very fast recovery with low side effects all documented by a thorough clinical and scientific background. Ablatherm-HIFU is clearly the leading technology with a large and growing base of clear support in Europe. I believe it will be an important therapy in offering patients a more complete range of effective therapies, especially options that help the patient preserve his lifestyle to its fullest."
By partnering with Davanzia the exclusive distributor of Ablatherm-HIFU in Spain, EDAP is aiming at further establishing Ablatherm-HIFU as a therapeutic option in Spain. Davanzia is strongly committed to expanding RPP treatments using the dedicated Ablatherm device today in place at ICUA. Davanzia is regarded as an innovative company providing the medical community with the latest technological products and equipment. Offering solutions in a wide range of medical minimally invasive specialties and particularly urology. Over the last 5 years, Davanzia has been extremely successful in establishing GreenLight(TM) Laser System for BPH in Spain.
"We firmly believe that this partnership will be a great success for both companies as we share the same mission, focusing our activities in providing a portfolio of minimally invasive medical devices to the medical community," said Jorge Garcia, Chairman and CEO of Davanzia. "Davanzia is a prestigious and consolidated company that has reached a market leader position within the urology field with a skilled sales network committed to the launching of the Ablatherm-HIFU. We are very excited about this agreement and we are convinced that based on our sales force and market knowledge, the Ablatherm-HIFU will be quickly placed in a successful position in the Spanish market."
Spain now joins a growing list of countries offering Ablatherm-HIFU in Europe where more than 100 centers in major countries including France, Germany, Italy, the United Kingdom, Norway, Portugal, Poland, Belgium, Austria, and Switzerland provide physicians trained in using HIFU for prostate cancer.
"The launch of Ablatherm-HIFU services in Spain continues the European rollout of HIFU for prostate cancer in major urology centers," said Hugues de Bantel, CEO of EDAP. "Clearly HIFU is accelerating in Europe where it is being adopted by many of the top urology centers in more countries. We are grateful to add another highly regarded center and well known distributor to our list of clinical and sales chAmpions advancing the case for Ablatherm-HIFU in Europe."
Davanzia has a wide commercial network covering the whole country with offices in the main Spanish cities. The central office is located in Madrid. Further details are available online at http://www.davanzia.com .
About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option or patients who failed radiotherapy treatment. The company is also developing this technology for the treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).
For more information on the Company, contact Halliburton Investor Relations at (972) 458-8000, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com or http://www.hifu-planet.es for more information on Ablatherm-HIFU in Spanish.
This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.
Source: EDAP TMS
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.